Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

UNITED STATES: In a Fight to the Finish, Saint Louis University Research Aims Knockout Punch at Hepatitis B (02.05.13)

Researchers have discovered a means to interrupt replication of hepatitis B virus by blocking the ribonuclease H (RNAseH) enzyme, which had previously eluded investigators. The breakthrough may lead to new drugs that can help suppress the virus enough to cure hepatitis B, reported John Tavis, Ph.D., Saint Louis University professor of molecular microbiology and immunology. The hepatitis B virus replicates by reverse transcription, a process in which two essential viral enzymes convert viral DNA to RNA and then back to DNA. Researchers have successfully assayed the first enzyme—a DNA polymerase—and developed five US Food and Drug Administration-approved drugs to target the enzyme. Although these drugs can suppress hepatitis B for a long time, the virus can multiply again years later, so hepatitis B-infected people must follow an expensive drug regimen for decades. Travis searched for 19 years for a way to measure RNAseH—the other enzyme necessary for hepatitis B replication—and devise ways to block it. The research team benefited from research breakthroughs with HIV, which replicates through a similar reverse transcription process. The team’s next task will be to study and measure other genotypes of the hepatitis B virus and to “improve the strength and speed of the RNAseH assay for high throughput screening….” Success with these tasks would clear the way for development and testing of drugs targeting RNAseH, which could combine with existing drugs to suppress hepatitis B completely. More than 350 million people worldwide have chronic hepatitis B, the principal cause of liver cancer. More than 1 million hepatitis B-infected people die from liver disease or liver cancer annually. The full report, “The Hepatitis B Virus Ribonuclease H Is Sensitive to Inhibitors of the Human Immunodeficiency Virus Ribonuclease H and Integrase Enzymes,” was published online in the journal PLOS Pathogens (2013; doi:10.1371/journal.ppat.1003125).


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in February 11, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.